Moderna Vice President and oncology portfolio lead Michelle Brown explains the newly announced experimental melanoma vaccine developed with Merck, how it works alongside the immunotherapy Keytruda, what the latest data show about lowering the risk of cancer returning, and what this could mean for patients moving forward.